F8 and hemophilia: HEK293 cells are currently in use to develop recombinant protein products for hemophilia therapy, i.e. a B-domain-deleted FVIII [43], and FVIIa-Fc, FIX-Fc, and FVIII-Fc fusion proteins [44–46].